

Defects in Pre-mRNA Processing as Causes of and Predisposition to Diseases

PETER STOILOV,^{1,*} ERAN MESHORER,^{2,*} MARIETA GENCHEVA,¹ DAVID GLICK,²
HERMONA SOREQ,² and STEFAN STAMM¹

ABSTRACT

Humans possess a surprisingly low number of genes and intensively use pre-mRNA splicing to achieve the high molecular complexity needed to sustain normal body functions and facilitate responses to altered conditions. Because hundreds of thousands of proteins are generated by 25,000 to 40,000 genes, pre-mRNA processing events are highly important for the regulation of human gene expression. Both inherited and acquired defects in pre-mRNA processing are increasingly recognized as causes of human diseases, and almost all pre-mRNA processing events are controlled by a combination of protein factors. This makes defects in these processes likely candidates for causes of diseases with complicated inheritance patterns that affect seemingly unrelated functions. The elucidation of genetic mechanisms regulating pre-mRNA processing, combined with the development of drugs targeted at consensus RNA sequences and/or corresponding proteins, can lead to novel diagnostic and therapeutic approaches.

OVERVIEW

RECENT PROGRESS IN THE HUMAN GENOME PROJECT has demonstrated that humans possess a surprisingly low number of genes, estimated to range around 25,000 to 40,000 (Lander *et al.*, 2001). A considerable fraction of the genes identified by different approaches now appears to be nonoverlapping, which implies a somewhat larger number of genes than previously assumed; however, the total number is not drastically modified (Hogenesch *et al.*, 2001). To create the proteome estimated to range between 90,000 and one million proteins (O'Donovan *et al.*, 2001; Harrison *et al.*, 2002; Hodges *et al.*, 2002), humans abundantly process their pre-mRNAs (Modrek *et al.*, 2001; Rubin, 2001) before protein translation occurs. This allows the production of multiple protein isoforms from a single gene. Transcription and pre-mRNA processing are both physically and functionally linked. This occurs by interaction of processing factors with the carboxy terminal domain of RNA polymerase II (Steinmetz, 1997) and by interaction of processing factors with transcription factors (Ge *et al.*, 1998). As a result, the choice of a particular promoter influences splice site selec-

tion (Cramer *et al.*, 1999, 2001). Finally, RNA processing factors are linked to chromatin organizing elements by scaffold attachment factor B (Nayler *et al.*, 1998). These associations imply that molecular defects in promoter structure and chromosomal localization of a gene can result in aberrant pre-mRNA processing.

While being transcribed, pre-mRNAs undergo a sequence of structural changes, such as capping, editing, splicing, and polyadenylation. In this process, the fidelity of each maturation step is controlled. Although the individual maturation steps can be biochemically separated, recent reports show that most of them are functionally coupled (Bentley, 1999; Minvielle-Sebastia and Keller, 1999; Maniatis and Reed, 2002). Defects in this fine-tuned RNA assembly line are increasingly recognized as causes of inherited human diseases (Philips and Cooper, 2000; Stoss *et al.*, 2000; Daoud *et al.*, 2000; Dredge *et al.*, 2001; Mendell and Dietz, 2001; Caceres and Kornblihtt, 2002; Nissim-Rafinia and Kerem, 2002). Changes in proteins functioning at different steps during the processing or changes in the efficiency of the processes can result in variation of genetic expression (Herbert and Rich, 1999). This may affect adaptation

¹University of Erlangen-Nuremberg, Institute of Biochemistry, 91054 Erlangen, Germany.

²The Hebrew University of Jerusalem, Institute of Life Sciences, Jerusalem 91904, Israel.

*These authors contributed equally to the preparation of this manuscript.

events, when the expression of the genetic information is altered according to changes in physiologic needs (Stamm, 2002). It should be pointed out that apart from pre-mRNA processing, which is a mechanism to enlarge the number of proteins made from the genome, there are a multitude of post-translational modifications, such as phosphorylation, acetylation, glycosylation, cleavage, etc., which create functional diversity among existing protein isoforms (O'Donovan *et al.*, 2001; Hodges *et al.*, 2002).

We propose that pre-mRNA processing has the potential to adapt the information stored in the genome to the physiologic requirements of circumstance, place, and time. The failure of such adaptation is frequently traced to defects in processing. These defects can manifest themselves directly in a disease or may remain silent until some internal or environmental stimulus (e.g., stress) or time (i.e., old age) allows the mutation to become apparent. Furthermore, the sequential nature of pre-mRNA processing raises the interesting possibility that pleiotropic diseases with a variable phenotype may be caused by specific compositions of *trans*-acting factors. For example, sporadic amyotrophic lateral sclerosis (ALS) was shown to be associated with a change in splicing patterns of the glutamate transporter gene EAAT2 (C. Lin *et al.*, 1998), as well as changes in nitric oxide synthase (NOS) mRNA splicing (Catania *et al.*, 2001). This indicates that the basic defect is in the pre-mRNA processing machinery, which gives rise to altered isoforms associated with the disease. While the culprit gene(s) may not yet be known, key proteins or RNAs controlling the affected processes can be subject to therapeutic efforts.

In this review, we will illustrate the variety of pathogenic defects that occur at each step of pre-mRNA processing in eukaryotic nuclei, and present examples for the mechanisms through which several mutations affect the pre-mRNA or the processing apparatus. To unravel the tangled interrelationships between these processes, we present examples of disease-causing defects in each of the relevant stages of mammalian pre-mRNA processing, describe stress-induced changes in pre-mRNA processing as an example of a disease predisposition, and finally discuss potential prospects for the development of novel therapeutic approaches.

DEFECTS IN PRE-mRNA PROCESSING AS A DIRECT CAUSE OF HUMAN DISEASE

pre-mRNA editing

Nucleotides in the pre-mRNA can be chemically modified in a process called RNA editing (Gott and Emeson, 2000; Gerber and Keller, 2001; Bass, 2002). During editing, adenosine or cytosine is deaminated, changing it into inosine (translated as guanine) or uridine, respectively. The editing of adenosines is catalyzed by adenosine deaminases acting on RNA (ADARs) (Reenan, 2001), whereas the editing of cytosines is catalyzed by Apobec-1 (Chester *et al.*, 2000). All of these enzymes are subsequently associated with heterogeneous nuclear ribonucleoprotein (hnRNP) complexes (Raitskin *et al.*, 2001), and can affect the removal of introns in the subsequent splicing reaction. For example, editing changes the splicing process in ADAR2 by changing an AA into an AG at the 3' consensus splice site of the ADAR2 pre-mRNA, suggesting a close inter-

action between editing and splicing (Rueter *et al.*, 1999). There are three ADAR genes in humans and genomic disruption experiments show that ADAR1 is essential in mice. The frequency of editing a particular nucleotide is species, tissue, and development stage specific. In obese Zucker rats, editing of hepatic apolipoprotein B mRNA was found to be 42% higher than in lean controls, corresponding to 1.8-fold increase in Apobec-1 catalytic activity in these rats (Phung *et al.*, 1996). ADAR1 expression was found to be upregulated in a mouse model of microvascular lung injury (MLI) as well as in cultured alveolar macrophages (MH-S cells) stimulated with endotoxin, or interferon-gamma, suggesting a plausible role for ADAR1 in the pathogenesis of MLI through induction by interferon (Rabinovici *et al.*, 2001). B cells with an unusual heavy- and light-chain antibody repertoire due to abnormal RNA editing were observed in patients suffering from rheumatoid arthritis, implying a role for RNA editing in autoimmune diseases (Meffre *et al.*, 2000). Despite the ubiquitous expression of ADAR1 and ADAR2, editing seems to be most prevalent in the brain, where 1 out of 17,000 nt is edited (Paul and Bass, 1998). Assuming an average length of 1 kb for an mRNA, this implies that up to 1 out of 20 brain transcripts is edited.

Perfectly matched RNA:RNA duplexes in the pre-mRNA appear to be the major determinant for ADAR editing. Such duplexes are created either by a natural regulatory "antisense" inversely oriented region in the predated transcripts or by transcriptional readthrough of adjacent genes in antisense orientation. An example for the first mechanism involves Apobec-1, the editing of which requires a conserved 26 nt sequence that contains an 11 nt mooring sequence located 4–5 nt downstream of the edited cytosine (Chester *et al.*, 2000). Another example refers to malignant tumors, which edit the NF1 neurofibromatosis transcripts more efficiently than benign tumors. Overexpressed Apobec-1, which catalyzes deamination of cytidines, induces murine tumorigenesis (Yamanaka *et al.*, 1995), suggesting that the corresponding gene may operate as a proto-oncogene (Chester *et al.*, 2000). Alternative splicing and RNA hyperediting was observed in the hematopoietic tyrosine phosphatase (*PTPN6*) gene in CD34⁺/CD117⁺ progenitor cells from acute myeloid leukemia patients. There, editing of adenosine (7866) to guanine in a putative branch site causes retention of intron 3, leading to abnormal accumulation of the aberrant splice variants (Beghini *et al.*, 2000). ADAR genomic disruption in *Drosophila* causes no obvious developmental phenotype but results in severe adult defects in motor control, flight, and mating. The defects increase in severity with age, concurrent with neurodegeneration (Palladino *et al.*, 2000; Reenan, 2001). Because editing is a prominent mechanism in the brain, impairments in this process were pursued in neurologic diseases. For example, Ca⁺⁺ conductance of AMPA receptors is regulated by the GluR2 subunit that is edited to exchange a glutamine with an arginine residue. GluR2 editing efficiency and mRNA levels were significantly lower in the ventral gray area of patients with ALS than in controls. These changes may account for the enhanced Ca⁺⁺ influx through AMPA receptors, which is a plausible cause for selective neuronal death in ALS (Takuma *et al.*, 1999). Reduced editing efficiency of GluR2 RNA was also observed in the prefrontal cortex of Alzheimer's disease patients and schizophrenics, as well as in the striatum of Huntington's disease patients (Akbarian *et al.*, 1995). This

points to neuronal activity as a contributing element of editing efficacy.

pre-mRNA splicing

Constitutive splicing. Almost all human genes contain introns that account for about 95% of the pre-mRNA (Lander *et al.*, 2001). Higher eukaryotes possess several types of introns, which have slightly different mechanisms of excision splicing: a major one, in which the introns are flanked by GU-AG dinucleotides and which accounts for more than 98% of all introns (Lander *et al.*, 2001), and a minor one in which introns are flanked by AU-AC dinucleotides (Tarn and Steitz, 1997). The major type has a subtype (about 1% of introns), for which the flanking nucleotides are GC-AG (Thanaraj and Clark, 2001).

During mRNA maturation those introns are excised and the remaining sequences, the exons, are joined. This process is performed by the spliceosome, a macromolecular complex comprising five small ribonucleoprotein particles (snRNPs) and at least 45 additional proteins (Neubauer *et al.*, 1998).

The recognition of an exon is guided by three sequence elements of the pre-mRNA: the 5' and 3' splice sites and the branchpoint. In addition, short sequences within or near the exon that can act as enhancers or silencers participate in exon recognition. Both the 5' and 3' splice site sequences, the enhancer/silencer elements, and the branch point associated with the splicing process are short (8–12 nt) and degenerate. Nevertheless, these sequences appear to be vulnerable to disease-causing mutations that destroy splice sites or create novel ones. Familial hypercholesterolemia is an autosomal dominant genetic lipoprotein disorder caused by defects within the low-density lipoprotein receptor gene. Some of its many mutations were shown to disrupt acceptor splice sites: an A to G substitution in the penultimate 3'-nucleotide of intron 16 (Lombardi *et al.*, 1993) and a G to C transposition at the last nucleotide of intron 7 (Yu *et al.*, 1999). In both cases a cryptic splice site was activated leading to the formation of a mutated receptor protein. Another example of a splice site mutation that leads directly to a disease phenotype is molybdenum cofactor deficiency (MoCoD), an inherited autosomal recessive disease that leads to early childhood death. Two bi-cistronic genes, *MOCS1* and *MOCS2*, are responsible for the generation of the molybdoenzymes, sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. A *MOCS1* splice site mutation leads to the deficiency of all these molybdenum cofactor related enzymes (Reiss *et al.*, 1999). Other splice site mutations, including those in the CFTR and beta-globin genes, resulting in cystic fibrosis and thalassemias, were previously compiled (Krawczak *et al.*, 1992; Nakai and Sakamoto, 1994). Mutations that alter the splicing process can occur outside both splice sites and enhancer/silencer elements. An example is the mutation described in a patient with ataxia-telangiectasia (ATM) which represents a deletion in an intron-splicing processing element crucial for accurate intron removal (Pagani *et al.*, 2002). The deletion of four nucleotides in this element abolishes a binding site for U1 snRNP and leads to activation of a cryptic exon, thus producing an abnormal mRNA transcript.

Changes in splicing factors can also be phenotypic. The appearance of splicing-associated diseases is often correlated with the plasticity and longevity of the affected cells. For example,

mutations in the human homologs of the splicing factor PRP31 or the splicing factor PRPC8 may cause retinitis pigmentosa, a progressive loss of rods and cones, which causes loss of over 90% of vision during childhood (McKie *et al.*, 2001; Vithana *et al.*, 2001).

Splice sites are highly degenerate, and additional regulatory sequences within the introns (intronic splicing enhancers) and the exons (exonic splicing enhancers) have to be present for proper exon recognition (Hertel and Maniatis, 1998). These sequences are also short and usually degenerate. They are bound by heterogeneous nuclear ribonucleoproteins, serine-arginine-rich (SR) proteins, and SR-like proteins. SR proteins are characterized by an RNA binding motif and an arginine-serine (i.e., RS)-rich domain located at the carboxyl terminus (Tacke and Manley, 1999; Graveley, 2000). This two-domain structure allows binding of SR proteins both to sequence elements on the pre-mRNA and to other components of the spliceosome. As a result, multimolecular complexes that interact with pre-mRNA at multiple sites are formed, allowing the recognition and bringing together of distant sequences in the excision-splicing event (Dreyfuss *et al.*, 2002).

SR protein binding sequences are frequently located in coding exons; therefore, their degeneration and the degeneration of the genetic code allows the flexibility needed for compatibility with the coding requirements of the gene product. The binding of SR proteins to their degenerate recognition sequences is intrinsically weak, resulting in a concentration-dependent regulation, for example, certain sequence elements are recognized only at higher SR protein concentration (Manley and Tacke, 1996). In addition to SR proteins, elements on the pre-mRNA bind to a diverse group of about 30 proteins, which are operationally defined as components of hnRNP complexes.

hnRNPs contain RNA binding motifs as well as several auxiliary domains, allowing those proteins to simultaneously bind to pre-mRNA and other proteins (Weighardt *et al.*, 1996; Krecic and Swanson, 1999). Both SR proteins and hnRNPs are present in tissue characteristic concentrations (Kamma *et al.*, 1995; Hanamura *et al.*, 1998). SR proteins can be stored and released from cellular storage compartments as speckles, through phosphorylation (Misteli *et al.*, 1998). As a result, the proper splice sites are recognized with a high degree of fidelity in an often tissue-specific manner.

An increasing number of alterations, both in normal and in alternative splicing, are being linked to defects in enhancer/silencer sequences (Cooper and Mattox, 1997; Philips and Cooper, 2000; Stoss *et al.*, 2000; Cartegni *et al.*, 2002). Several disease-relevant mutations are compiled in Table 1. As can be seen there, a number of these mutations are present in an exon, but do not change the protein sequence. Because they cause aberrant splice site selection, they can cause a disease, although they do not modify mRNA translation. Examples of these mutations include a T to C (L284L) mutation in tau exon 10 that disrupts an exonic splicing enhancer, causing frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) (D'Souza *et al.*, 1999), a C to G (R28R) mutation in porphobilinogen deaminase that results in exon 3 skipping, and which causes porphyria (Llewellyn *et al.*, 1996) and a A to G mutation in pyruvate dehydrogenase resulting in Leigh's encephalomyelopathy (De Meirleir *et al.*, 1994).

TABLE 1. MUTATIONS IN EXONIC REGULATORY SEQUENCES THAT CAUSE DISEASE

<i>Gene/disorder</i>	<i>Mutation</i>	<i>Effect</i>	<i>Reference</i>
SMN2 Spinal muscle atrophy (SMA)	Silent C>T conversion in exon 7	Disrupts ESE, skipping of exon 7	(Covert <i>et al.</i> , 1997; Jablanka <i>et al.</i> , 2000; Lefebvre <i>et al.</i> , 1995, 1997; Lorson and Androphy, 2000; Lorson <i>et al.</i> , 1999; Monani <i>et al.</i> , 2000; Vitali <i>et al.</i> , 1999)
SMN1 Spinal muscle atrophy (SMA)	425del5 W102X	Skipping of exon 3	(Sossi <i>et al.</i> , 2001)
Beta-hexaminidase Beta-subunit Sandhof disease	Exon 11 P417L C>T conversion at nucleotide 8 Intron 10 A>G conversion at position -17	Disrupts an ESE. Causes use of a cryptic splice site at nucleotide +112 Causes usage of a cryptic splice site at position -37. Disrupts ISE. The conversion also disrupts a putative branch point	(Fujimaru <i>et al.</i> , 1998)
Tau Frontotemporal Dementia with Parkinsonism linked to chromosome 17	Intron 10: +13 A>G, +14 C>T, +16 C>T, IVS10+3 G>A Exon 10: L284L T>C, S305S T>C, S305N G>A Exon 10: N297K T>G, del 280K (AAG deletion)	Disrupt ISE IVS10+3 G>A improves slightly the splice site score (from 6.8 to 7.0) Disrupt ESE S305N G>A improves the splice site Disrupts ESE	(D'Souza <i>et al.</i> , 1999; D'Souza and Schellenberg, 2000; Hasegawa <i>et al.</i> , 1999; Hutton <i>et al.</i> , 1998; Iijima <i>et al.</i> , 1999; Spillantini <i>et al.</i> , 1998; Stanford <i>et al.</i> , 2000)
Porphobilinogen deami- nase Acute intermittent por- phyria	R28R, C>G	Skipping of exon 3	(Llewellyn <i>et al.</i> , 1996)
Integrin GPIIIa Glanzmann thrombasthenia	C>A at position +16 and silent G>A at +134 of exon 9	Skipping of exon 9	(Jin <i>et al.</i> , 1996)
Fumarylacetoacetate hydrolase Hereditary tyrosinemia type 1	N232N C>T	Skipping of exon 8	(Ploos van Amstel <i>et al.</i> , 1996)
Pyruvate dehydrogenase E1 alpha Leigh's encephalomyelopathy	Silent A>G	Aberrant splicing of exon 6	(De Meirleir <i>et al.</i> , 1994)
MNK Menkes disease	Gly>Arg G>A	Skipping of exon 8	(Das <i>et al.</i> , 1994)
Adenosine deaminase Severe combined immu- nodeficiency disease	R142X G>A and C>T in the same codon	Skipping of exon 5	(Santisteban <i>et al.</i> , 1995)

TABLE 1. MUTATIONS IN EXONIC REGULATORY SEQUENCES THAT CAUSE DISEASE (CONT'D)

<i>Gene/disorder</i>	<i>Mutation</i>	<i>Effect</i>	<i>Reference</i>
Arylsulfatase A Metachromatic leuko- dystrophy	Thr409Ile C>T	Activates a cryptic splice site	(Hasegawa <i>et al.</i> , 1994)
Fibrillin-1 Marfan syndrome	Silent C>T in exon 51	Skipping of exon 51	(Liu <i>et al.</i> , 1997)
CYP 27 Cerebrotendinous xan- thomatosis	Silent G112G G>T in exon 2	Creates a cryptic splice site. In addition it causes skipping of the entire exon 2	(Chen <i>et al.</i> , 1998)
CD45 Individuals do not suffer from obvious immunodeficiency, but it is notable that no homozygotes have been described. Associated with Multiple sclerosis in the American population.	Silent C>G at position 77 of the alternative exon 4	Disrupts an ESE. Constitutive inclusion of exon 4	(Jacobsen <i>et al.</i> , 2000; Lynch and Weiss, 2001; Zilch <i>et al.</i> , 1998)
Beta-globin Beta-Thalassemia	T->G transversion in position 705 of intron 2	Activates cryptic 3' splice site in intron 2	(Dobkin and Bank, 1983; Dobkin <i>et al.</i> , 1983)
BRCA1 Breast and ovarian cancer	E1694X G>T	Disrupts ESE and causes skipping of exon 18	(Liu <i>et al.</i> , 2001)
NF-1 Neurofibromatosis type 1	Y2264X C>A, C>G R304X C>T Q756X C>T	Skipping of exon 37 Skipping of exon 7 Skipping of exon 14	(Ars <i>et al.</i> , 2000a, 2000b; Hoffmeyer <i>et al.</i> , 1998; Messiaen <i>et al.</i> , 1997)
DMPK Myotonic dystrophy	Expanded (CUG)>40 in the 3' UTR of DMPK	Two possibilities: CUG repeats sequester CUG-BP and therefore prevent it from its normal function; or expanded CUG repeats alter the alternative splicing of the DMPK-mRNA by developing a new 3' splice site.	(Phillips <i>et al.</i> , 1998; Tiscornia and Mahadevan, 2000)

The affected gene (bold) and the disease is listed in the first column, the mutation in the second column. The effect on pre-mRNA splicing and the assumed mechanism are listed in the third column.

Alternative splicing. In mammals, including humans most genes generate several mRNAs from a single gene by involvement of more than one pattern of excision-splicing choices, a process called alternative splicing (Graveley, 2001). For example, it has been estimated that 59% of all human genes on chromosome 22 are alternatively spliced. Because this number is based on comparison of expressed sequence tags (ESTs) with genomic data, the real number is likely to be higher, as low abundant mRNAs are not taken into account, and ESTs are biased towards the mRNA 3' ends (Lander *et al.*, 2001). It is likely that the fine-tuned balance between SR proteins, hnRNPs, splice sites, and enhancer/silencer elements can be modulated to achieve a change in pre-mRNA exon usage (Grabowski,

1998; Hastings and Krainer, 2001). The levels of SR proteins and hnRNPs vary among tissues (Hanamura *et al.*, 1998), and can be further modulated by releasing SR proteins from intranuclear storage compartments, such as speckles, through protein phosphorylation (Misteli *et al.*, 1998). Alternative splicing is often tightly regulated in a cell type- and/or development-specific manner; cells from the immune and the nervous systems use this mechanism most abundantly (Grabowski and Black, 2001; Lander *et al.*, 2001).

The phenotype of most neurodegenerative diseases manifests itself later in life, and some missplicing events are causally related to such diseases. Mutations in tau exon 10 that are implicated in FTDP-17, are good examples of such a complex phe-

notype. Frontotemporal dementias represent a rare form of pre-senile dementia, and are clinically defined by behavioral and personality changes, psychomotor stereotypes, as well as loss of judgment and insight. The neuropathologic findings include asymmetric frontotemporal atrophy and the presence of filamentous tau deposits. FTDP-17 was mapped to the tau locus on chromosome 17, and at least 50 kindreds are affected world wide (Hutton *et al.*, 1998). Tau transcripts undergo complex regulated splicing in the mammalian nervous system. The alternative splicing of tau's exon 10 is species specific: this exon is excised in adult humans, but in the adult rodent brain, it is used constitutively. Exon 10 encodes one of the four microtubule binding sites of tau. In the normal brain, tau isoforms containing and lacking exon 10 sequences are balanced. A disruption of the proper distribution of tau isoforms is observed in the pathology of several tauopathies. In FTDP-17, sporadic corticobasal degeneration and sporadic progressive supranuclear palsy, tau proteins containing exon 10 sequences are overproduced, whereas in sporadic Pick's disease tau proteins lacking exon 10 sequences are predominant (Goedert *et al.*, 1999; Spillantini and Goedert, 2001).

Mapping of elements in tau exon 10 has revealed a potential stem-loop structure at the 5' splice site, which may be involved in regulation of exon 10 splicing (Hutton *et al.*, 1998). In addition, a complicated set of exonic enhancer elements was identified (D'Souza and Schellenberg, 2000; Gao *et al.*, 2000). The disruption of these elements by mutation apparently disturbs the balance between the different tau isoforms and causes the aggregation of improperly spliced gene products associated with neurodegeneration.

Misdirected regulation of alternative splicing is observed in several additional neurologic disorders. One example includes schizophrenia. The alternative splicing of the long (L) and short (S) gamma2 subunit mRNAs of the gamma-amino butyrate type A (GABA-A) receptor was shown to be modified in the prefrontal cortex of schizophrenic patients. The reduction in gamma2S and the increase in gamma2L mRNAs were suggested to result in less active GABA-A receptors with severe consequences for cortical integrative function (Huntsman *et al.*, 1998). Postmortem brain investigations revealed alternative splicing of *N*-methyl-D-aspartate (NMDA) R1 (NRI) carboxy-terminus isoforms in the superior temporal gyrus of schizophrenic patients (Le Corre *et al.*, 2000). Schizophrenia was further shown to be associated with alternative splicing of the neural cell adhesion molecule (N-CAM) mRNAs. Elevated levels of the variable alternative spliced exon (VASE) were found in CSF of schizophrenic patients (Vawter *et al.*, 2000).

3' End processing and nuclear export

Once RNA polymerase II encounters the highly conserved AAUAAA polyadenylation signal, 3' end processing takes place (Dreyfuss *et al.*, 2002). A minimum of six factors are required for 3' end formation: cleavage and polyadenylation factors (CPSF), cleavage stimulation factor (CSF), cleavage factors I and II, poly(A) polymerase (PAP), and poly(A) binding protein. These factors recognize the AAUAAA signal and a downstream element and then perform cleavage of the RNA at its 3' end as well as its polyadenylation.

Thalassemia is one of the world's most common hereditary

diseases. Common forms of both alpha- and beta-thalassemia are both associated with point mutations within the polyadenylation signals of alpha-globin and beta-globin genes, respectively (Higgs *et al.*, 1983; Orkin *et al.*, 1985), leading to the generation of abnormal hemoglobin. Patients suffer from moderate anemia with microcytosis and hypochromia.

A guanosine to adenosine mutation in the 3' end of the prothrombin gene is a common cause for thromboembolic events. This mutation is positioned at the site where the pre-mRNA is cleaved during processing and then polyadenylated. The mutation leads to more efficient cleavage of the pre-mRNA, and consequently, to elevated amounts of prothrombin mRNA and an increase of the blood prothrombin concentration (Gehring *et al.*, 2001). The mutation is common, with an allele frequency of 1.2%, and may represent an advantage in young age by providing better blood clotting, for example, during childbirth (Poort *et al.*, 1996). Another example for misregulation of 3' end formation is autosomal dominant oculopharyngeal muscular dystrophy (OPMD), an adult-onset disease caused by a (GCG)_{8–13} repeat expansion in the polyadenylation binding protein 2 (PABP2) gene. Patients suffer from progressive dysphagia, eyelid ptosis, and proximal limb weakness, and its pathologic hallmark is the accumulation of intranuclear inclusions in muscle fibers due to abnormal mRNA processing (Brais *et al.*, 1998). The export of mRNAs into the cytosol is mediated by nuclear export factors (NXFs) believed to be the molecular link between the hnRNP complexes and the nuclear pore complex (Herold *et al.*, 2000). Loss of the NXF5 protein, which is most likely a novel nuclear RNA export factor, results in X-linked mental retardation, but the molecular details remain to be worked out (J. Lin *et al.*, 2001).

Nonsense mutations, exon skipping, and mRNA degradation

Premature stop codons may lead to an alternatively spliced variant that skips the mutated exon (Dietz *et al.*, 1993), a phenomenon referred to as nonsense-mediated altered splicing. Nonsense-mediated altered splicing was thought to require nuclear recognition by the spliceosome of "cytosolic" translational signals but recent research on the *BRCA1* gene suggests it can result from disruption of a splicing enhancer located in the coding sequence (H.X. Liu *et al.*, 2001). A related mechanism is nonsense mediated decay (NMD), also known as RNA surveillance. In both cases, the nascent mRNA is screened for nonsense mutations. NMD takes place if the distance between a stop codon and the downstream exon-exon junction is larger than 50–55 nt (Hentze and Kulozik, 1999; Maquat and Carmichael, 2001). Such stop codons are considered premature, and NMD leads to decapping and degradation of the mRNA. Because about 25% of all alternatively spliced exons introduce alternative stop codons (Stamm *et al.*, 2000), NMD together with alternative splicing is a common mechanism to downregulate gene expression. The location of exon-exon junctions is memorized in the cytosol by binding of the Y14 protein to the junction (Kim *et al.*, 2001; Kim and Dreyfus, 2001). Messenger RNA stability is also decreased by adenylate, uridine-rich instability elements (ARE) that accelerate mRNA deadenylation. AREs are usually located in the 3'UTR and bind to hnRNPs of the HuR/HuA family (Brennan and Steitz, 2001).

Chain termination mutations are frequent causes for disease in humans. For example, 89% of mutations in the ATM gene that causes ataxia-telangiectasia and 77% of mutations in BRCA1 give rise to premature stop codons (Couch and Weber, 1996; Gilad *et al.*, 1996). The mRNAs with premature stop codons rarely produce truncated proteins but are rather subject to non-sense-mediated decay. Typically, these mutations result in a loss-of-function phenotype. The involvement of NMD in beta-thalassemia, gyrate dystrophy, and Marfan syndrome has been recently reviewed (Frischmeyer and Dietz, 1999). A change in RNA stability is often associated with cancer, due to stabilization of mRNAs that promote tumor progression, such as immunosuppressive cytokines and angiogenic growth factors. Interestingly, HuR, a factor that stabilizes mRNAs by binding to AREs is constitutively expressed in brain tumors, and its expression pattern correlates with the grade of malignancy (Nabors *et al.*, 2001).

DEFECTS IN PRE-mRNA PROCESSING THAT PREDISPOSE TO A DISEASE

Stress-induced alterations

A number of mutations do not show a phenotype directly, but rather remain silent, until some external stimulus allows the mutation to become apparent in certain cell types or developmental and aging phases. This implies that diagnostic and therapeutic approaches might be developed to anticipate, and prevent the damage caused by such defects. The consequences of stress present an example of such a circumstance.

In recent years, a growing body of evidence links alternative splicing adaptation to stressful internal and external changes in cells and tissues. The term stress, adapted from physics, spans physical, chemical, and psychologic pressures that are potentially detrimental and sharing common features (McEwen, 1999). The cellular signaling pathways affecting alternative splicing under modified stimuli are poorly understood, although recent efforts by several investigators yielded interesting findings. Activation of the MKK_{3/6}-p38 cascade was shown to modify the subcellular distribution of hnRNP A1, resulting in modified alternative splicing (van der Houven van Oordt *et al.*, 2000). The ability of hnRNP K to silence mRNA translation also requires relocation to the cytoplasm, which is dependent on the stress-activated ERK MAP-kinase pathway (Habelhah *et al.*, 2001). The ERK/MAP-kinase pathway was shown to be involved, upon activation of T cell lymphocytes, in the alternative splicing of CD44 by retaining exon v5 sequence in the mature mRNA (Weg-Remers *et al.*, 2001). Intriguingly, some of the evoked changes in alternative splicing produce transcripts that have antagonistic cellular actions. For example, heat-shock factor 4 generates by alternative splicing both an activator and a repressor of downstream heat-shock genes (Tanabe *et al.*, 1999). Also, alternative splicing of the apoptotic gene, *bcl-x*, substitutes a large protein product, Bcl-xL, which inhibits cell death, for a smaller one, Bcl-xS, which antagonizes this ability under certain conditions (Boise *et al.*, 1993). Neuronal activity-dependent alternative splicing was shown for the rat homolog of the human splicing regulator transformer 2 gene, *hTra2-beta*, in the rat brain (Daoud *et al.*, 1999).

Stress-induced changes in alternative splicing have been demonstrated for the transcripts of a variety of genes, including those for heat-shock factors 1 (Goodson *et al.*, 1995) and 4 (Tanabe *et al.*, 1999), the apoptotic gene *bcl-x* (Boise *et al.*, 1993), genes for several Jun N-terminal kinases (JNKs) involved in regulating transcription factors (Holland *et al.*, 1997; Y. Zhang *et al.*, 1998) and the human genes for the ATF family of transcription factors (Goetz *et al.*, 1996). A change in alternative splicing following stress was demonstrated, for example, for the glucocorticoid receptor (GR). Perinatal manipulations and postnatal handling were shown to selectively elevate GR mRNA containing a hippocampus-specific exon, which facilitates adaptation to the conditions of stress. Prenatal glucocorticoid exposure, in turn, increased hepatic GR expression by producing a minor exon 1 variant (McCormick *et al.*, 2000).

Glucocorticoids also regulate the splicing pattern of the murine *Slo* gene encoding a brain K⁺-channel, which depends on neuronal depolarization (Xie and McCobb, 1998). Hypoxia was shown to induce the alternative splicing of the presenilin-2 gene, generating an isoform also found extensively in the brain of Alzheimer's disease patients (Sato *et al.*, 1999). A detailed study of SR proteins under ischemic conditions in the brain revealed that some of them translocate from the nucleus to the cytosol after an ischemic event, which could explain the observed changes in splice site selection (Daoud *et al.*, 2002). Although splice site selection can serve as a physiologic adaptation to a change in the external conditions, the above examples show that these changes may also contribute to pathophysiologic events. One extensively studied example is a change in the acetylcholinesterase (AChE) pre-mRNA processing (Soreq and Seidman, 2001). Here, various external stimuli were shown to induce rapid, long-lasting changes of neuronal AChE pre-mRNA splicing. These include psychologic stress (Kaufer *et al.*, 1998), environmental stimuli (anti-AChE intoxication) (Shapira *et al.*, 2000), head injury (Shohami *et al.*, 2000), and inherited AChE overexpression (Meshorer *et al.*, 2002). Although most of the currently available evidence on this splicing shift refers to animal studies, a recent screen demonstrated accumulation of the stress-induced AChE-R variant in the cerebrospinal fluid (CSF) of patients with stress indices, indicating that these pathologic changes also occur in humans (Tomkins *et al.*, 2001).

Tumorigenesis

Many cases of different cancers are also associated with changes in the splicing pattern of various genes. For example, 43% of neurofibromatosis type 1 (NF1) defects are caused by aberrantly spliced pre-mRNA (Ars *et al.*, 2000b). Furthermore, the splicing pattern of the adhesion molecule CD44 changes during tumorigenesis (Stickeler *et al.*, 1999) and melanomas were found to be associated with elevated levels of the delta1b and delta1d alternatively spliced transcripts of the tyrosinase gene compared to normal skin melanocytes (LeFur *et al.*, 1997). Different splice variants of the estrogen receptor (ER) (e.g., skipping of exons 2, 3, 4, 5, or 7 (Q.X. Zhang *et al.*, 1996)) were found to be associated with human breast cancer. Resistant acute myeloid leukemia was shown to be associated with high incidence of alternatively spliced forms of deoxycytidine

kinase, which could contribute to the process of cytarabine resistance in these patients (Veuger *et al.*, 2000). It was shown that SR proteins display tumor stage-specific changes in mammary tumorigenesis (Stickeler *et al.*, 1999), which suggests that concentration alterations of these regulatory proteins could orchestrate the use of different splice sites in tumors.

Pathologies associated with changes in alternative splicing patterns without specific mutations in splice sites may reflect defects in an upstream splicing modifier. Differential expression of hnRNPs, snRNPs, SR, and SR-like proteins could, in principle, be the cause for such pathologies. For example, positional cloning revealed segregation with prostate cancer of *ELAC2*, which displays sequence similarity to the 73-kD a subunit of mRNA 3' end cleavage and polyadenylation specificity factor (CPSF73) (Tavtigian *et al.*, 2001), suggesting mRNA processing abnormalities in prostate cancer.

OUTLOOK FOR THERAPY

A general theme in pre-mRNA processing is a high fidelity and specificity achieved by combinatorial control. This is exemplified in the redundancy of the relevant sequences, the modular composition of the corresponding proteins, and the cascade pattern of the involved processes. The examples compiled above show that numerous defects in pre-mRNA processing contribute to human diseases. This, in turn, calls for the development of diagnostic and therapeutic means targeted at pre-mRNA processing. Different approaches have been tested in various models of diseases that are summarised in Table 2.

Antisense oligonucleotides

The danger of nonspecificity in targeting pre-mRNA processing can be avoided by design of selective agents, such as oligonucleotides (Mercatante and Kole, 2000) (Fig. 1A). Beta-thalassemia in human erythroid cells may be treated with modified oligonucleotides binding to mutated splice sites, showing that this approach is feasible (Lacerra *et al.*, 2000). Antisense oligoribonucleotides targeted against an aberrant 5' splice site were also used to partially reverse the aberrant splicing of beta-globin mRNA in beta-thalassemia/HbE disease cells in culture (Shirohzu *et al.*, 2000). In cultured cells, targeting of splice sites by antisense oligonucleotides was shown to reverse the inclusion of tau exon 10 in a model of FTDP-17 (Kalbfuss *et al.*, 2001) and to increase the inclusion of SMN exon 7, associated with spinal muscular atrophy (Lim and Hertel, 2001). 2'-O-Methylated antisense oligoribonucleotides were used to modify the splicing pattern of the dystrophin pre-mRNA in the mdx mouse model of Duchenne muscular dystrophy (DMD). DMD is a severe muscle disease caused by defects within the dystrophin gene. Its milder version, Becker muscular dystrophy, is caused by in-frame deletions that generate a shorter but minimally functional dystrophin protein. This suggested removal of the deficient part in the mutated dystrophin as a therapeutic approach. The oligoribonucleotides blocked binding sites involved in normal dystrophin pre-mRNA splicing, inducing excision of exon 23 with the mdx nonsense mutation, without disrupting the reading frame (Mann *et al.*, 2001).

Finally, the detrimental accumulation of the stress-induced AChE-R mRNA can be prevented by antisense oligonucleotides,

TABLE 2. OVERVIEW OF THE THERAPEUTIC STRATEGIES

Drug/substance	Gene/disease tested	Reference
Antisense oligonucleotides		
Modified oligonucleotides	β -thalassemia	(Shirohzu <i>et al.</i> , 2000)
	FTDP-17	(Kalbfuss <i>et al.</i> , 2001)
	SMN2/Spinal muscular atrophy	(Lim and Hertel, 2001)
	Dystrophin/Duchenne muscular dystrophy	(Mann <i>et al.</i> , 2001)
	AChE-R	(Shohami <i>et al.</i> , 2000; Lev-Lehman <i>et al.</i> , 2000)
RNAi		
RNA oligonucleotide	Multiple	(Cellotto and Graveley, 2002)
Ribozymes		
Ribozyme	Mutant β -globin	(Lan <i>et al.</i> , 1998)
	p53 mRNA <i>trans</i> -splicing	(Watanabe and Sullenger, 2000)
SMaRT		
Targeting RNA	CFTR exon 10	(Mansfield <i>et al.</i> , 2000)
Low molecular weight drugs		
Neomycin	FTDP-17	(Varani <i>et al.</i> , 2000)
Aclarubicin	SMN2/spinal muscular atrophy	(Andreassi <i>et al.</i> , 2001)
Sodium butyrate	SMN2/spinal muscular atrophy	(Chang <i>et al.</i> , 2001)
Expression of trans-acting factors		
tra2- β 1	SMN2/spinal muscular atrophy	(Hofmann <i>et al.</i> , 2000)
clk-1	tau/FTDP-17	(Hartmann <i>et al.</i> , 2001)

The principal action is shown in a gray box. Drugs and substances used are in the first column, genes and diseases tested are listed in the second column.

with potentially promising prospects for the treatment of head injury (Shohami *et al.*, 2000) and exposure to organophosphate acetylcholinesterase inhibitors (Lev-Lehman *et al.*, 2000).

RNAi

The most recent and yet mechanistically illusive phenomenon that may lead to future therapeutic technologies is RNA interference (RNAi). Found by serendipity, RNAi acts to cause target-specific gene silencing by destabilizing cellular RNA (Carthew, 2001; Zamore, 2001). Intriguingly, RNAi was demonstrated to be effective *in vivo* in *Caenorhabditis elegans* when the nematodes digested engineered bacteria that expressed double-stranded RNA of the *C. elegans* *unc-22* gene. These nematodes developed similar phenotypes of *unc-22* mutants (Timmons and Fire, 1998). RNAi was shown to suppress gene-expression levels in mammalian cells using either short (e.g., 22-mer) double-stranded RNAs (Elbashir *et al.*, 2001), or long (e.g., 500-mer) dsRNAs (Paddison *et al.*, 2002), as well as stable “knock-down” of genes using long hairpin dsRNA (Paddison *et al.*, 2002). Recently, RNAi was used to selectively degrade alternatively spliced mRNA isoforms in *Drosophila* by treating cultured cells with dsRNA corresponding to an alternatively spliced exon (Celotto and Graveley, 2002). This powerful tool may come to occupy an important role in future gene therapy (Fig. 1B).

Ribozymes

Ribozymes are RNAs that catalyze a limited number of reactions in cells, especially cleavage of other nucleic acids (Lewin and Hauswirth, 2001). The ribozymes under development for therapy are based on small naturally occurring RNAs, such as the hammerhead and the hairpin, derived from plant virus satellite RNA, the tRNA processing ribonuclease P (RNase P), and group I and group II ribozymes, which occur as introns in organelles and bacteria but can be engineered to act in *trans* on RNA or DNA. Group I introns have been used to repair defective mRNAs by *trans*-splicing, for example, to replace defective p53 mRNA with the wild type, resulting in close to full restoration of the wt p53 activity (Watanabe and Sullenger, 2000). A *trans*-splicing group I ribozyme was also shown to be a useful candidate for altering the mutant beta-globin transcripts in erythrocyte precursors derived from peripheral blood of sickle cell disease subjects. Sickling beta-globin, the beta-chain of HbS, transcripts were converted into messenger RNAs that encode the nonsickling beta-globin (Lan *et al.*, 1998).

SMaRT

Another novel approach for gene therapy is Spliceosome-Mediated RNA *Trans*-splicing (SMaRT) (Puttaraju *et al.*, 1999). SMaRT is an emerging technology in which RNA molecules are designed to code a specific pre-mRNA by utilizing *trans*-splicing reaction between the introduced RNA and its pre-mRNA target (Fig. 1C). During the splicing reaction, a part of the pre-mRNA is first excised in a concerted reaction, followed by the remaining exons being ligated. This reaction occurs normally in *cis*, for example, on a single pre-mRNA molecule that

is transiently attached to the spliceosome. However, splicing can also take place between two independently transcribed sequences, a process called *trans*-splicing that is found in trypanosomes, nematodes, flatworms, and plant mitochondria. Because the mechanisms of *trans*- and *cis*-splicing are similar, it is possible to generate RNA molecules that would be processed by the spliceosome in a *trans*-splicing reaction, which can be used to repair a defective pre-mRNA molecule by exchanging parts of it (Puttaraju *et al.*, 1999).

SMaRT was demonstrated successfully using plasmids expressing mutant CFTR minigenes. When 293T cells were co-transfected with both the mutated and the normal constructs, they produced a *trans*-spliced mRNA in which the mutant exon 10 was replaced by a normal one. This *trans*-splicing reaction was further shown to produce mature CFTR protein (Mansfield *et al.*, 2000).

Low molecular weight drugs

The use of RNA-binding antibiotics such as gentamicin, chloramphenicol, and tetracycline clearly shows that RNA and/or RNA interacting proteins can be targeted by drugs (Varani *et al.*, 2000; Xavier *et al.*, 2000). Targeting pre-mRNA processing pathways could therefore be a new therapeutic approach. Aclarubicin, an anticancer drug, was shown to change the alternative splicing pattern of SMN2 in cells derived from spinal muscular atrophy patients. In this disease, the SMN1 gene is deleted, and an almost identical human gene, SMN2, cannot compensate for the loss, because it is differently spliced. Aclarubicin treatment can reverse this wrong splicing pattern, which results in formation of full length SMN protein. Although it is yet unknown how aclarubicin changes alternative splicing (Andreassi *et al.*, 2001), this is a promising example of pre-mRNA therapeutics (Fig. 1D).

Indirect effects

The combinatorial regulation of pre-mRNA processing may also result in indirect effects that have to be considered for any therapeutic approach. This is illustrated by the change in alternative splicing patterns of human cardiac troponin T in patients with myotonic dystrophy. Myotonic dystrophy is caused by a CUG repeat extension in the 3' UTR of the cAMP-dependent protein kinase gene (Korade-Mirnic *et al.*, 1998). This repeat extension causes a sequestration of a CUG-binding protein, which results in a change of cardiac troponin T pre-mRNA splicing patterns (Philips *et al.*, 1998; Lu *et al.*, 1999). Increased expression of the CUG-binding protein in skeletal muscle tissue of myotonic dystrophy patients further results in aberrant alternative splicing of the insulin receptor pre-mRNA, with predominant expression of the nonmuscle isoform (Savkur *et al.*, 2001). Finally, the splicing pattern of mutated alleles, for example in the cystic fibrosis CFTR gene, strongly depends on the cell type (Rave-Harel *et al.*, 1997), explaining why natural mutations frequently have a tissue- or cell type-specific effect [e.g., male sterility due to impaired testicular splicing of the CFTR transcripts (Kerem and Kerem, 1996)]. A possible explanation would be a cell type-specific set of regulatory factors. Skipping of CFTR exon 9 was shown to depend on expression of a factor binding a polymorphic repeated sequence in its 3' splice site, TDP-43 (Buratti *et al.*, 2001). However, this




FIG. 1. Principles of different therapeutic strategies. Exons are indicated as boxes, introns as thick lines. Different coloring indicates alternative exon usage. Splicing patterns are shown as thin lines. Small molecular weight substances are shown as small yellow polygons. Base pairing is indicated by thin lines. (A) Antisense oligonucleotides (thick red line) can bind to a splice site and prevent its usage (left), which favors exon skipping (right). (B) Misspliced mRNAs can be eliminated by RNAi using specific siRNAs (green lines). As a result, the undesired splice product is eliminated (right). (C) Undesired exons (red) can be replaced using SMaRT (yellow) constructs, which results in the exchange of an exon in a *trans*-splicing reaction (right). (D) Small molecular weight molecules (yellow) can change splicing patterns, for example, by stabilization of secondary pre-mRNA structures. (E) Phosphorylation of splicing regulatory proteins changes their interaction with RNA or other proteins and can result in an altered splicing product in the presence (top) or absence (bottom) of a kinase activity (black enzyme).

effect also depends on the simultaneous expression of SR proteins. It is clear that this combinatorial control will impact on every therapeutic intervention; therefore, the effects of existing drugs on pre-mRNA processing of yet unknown gene products, in addition to their target molecules, should be taken into consideration. Nevertheless, the importance of such processes points to the RNA transcripts themselves, as well as their cognate proteins, as novel targets for therapeutic intervention.

Trans-Acting factors

Spinal muscular atrophy illustrates how the knowledge of the molecular mechanisms regulating pre-mRNA processing allows the development of rational therapies. The disease is caused by the loss of the Survival of Motor Neuron gene 1 (*SMN1*) and subsequent loss of the SMN protein. As noted above, a nearly identical gene, *SMN2*, gives rise predominantly to a shorter mRNA form, producing a modified SMN protein. Therefore, *SMN2* cannot compensate for the absence of SMN protein. The loss of the *SMN1* gene can, however, be compensated in cultured cells by manipulating the splicing pattern of *SMN2*, through increasing the amount of a regulatory factor, tra2-beta1 that binds to a purine-rich enhancer of the alternative exon (Hofmann *et al.*, 2000). Several SR proteins bind to this enhancer, and their ratio can also be changed by sodium butyrate. Administration of this drug to lymphocytes of spinal muscular atrophy patients results in an altered splicing pattern of *SMN2*, which could also compensate for the loss of *SMN1* (Chang *et al.*, 2001).

In FTDP-17 mutations, splicing of tau exon 10 is mis-regulated through complex changes in the composition of several splicing enhancers (D'Souza and Schellenberg, 2000). These mutations can be overcome by expressing cdc2 like kinases (clk1-4) (Nayler *et al.*, 1997). These kinases phosphorylate SR proteins and alter tau exon 10 splicing, most likely by changing the phosphorylation-dependent composition of the enhancer complex (Hartmann *et al.*, 2001; Fig. 1E). Low molecular weight drugs activators of clk1-4 kinases, when identified, may be therapeutically beneficial for this devastating disease.

ACKNOWLEDGMENTS

This work was supported by the Deutsche Forschungsgemeinschaft (SFB473, Sta399/5-1, Sta456/1-1 and Sta399/7-1, to S.S.) and the U.S. Army Medical Research and Materiel Command (DAMD 17-99-1-9547, to H.S.).

REFERENCES

- AKBARIAN, S., SMITH, M.A., and JONES, E.G. (1995). Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. *Brain Res.* **699**, 297-304.
- ANDREASSI, C., JARECKI, J., ZHOU, J., COOVERT, D.D., MONANI, U.R., CHEN, X., WHITNEY, M., POLLOK, B., ZHANG, M., ANDROPHY, E., *et al.* (2001). Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. *Hum. Mol. Genet.* **10**, 2841-2849.
- ARS, E., SERRA, E., DE LA LUNA, S., ESTIVILL, X., and LAZARO, C. (2000a). Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA. *Nucleic Acids Res.* **28**, 1307-1312.
- ARS, E., SERRA, E., GARCIA, J., KRUYER, H., GAONA, A., LAZARO, C., and ESTIVILL, X. (2000b). Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. *Hum. Mol. Genet.* **9**, 237-247.
- BASS, B.L. (2002). RNA editing by adenosine deaminases that act on RNA. *Annu. Rev. Biochem.* **71**, 817-846.
- BEGHINI, A., RIPAMONTI, C.B., PETERLONGO, P., ROVERSI, G., CAIROLI, R., MORRA, E., and LARIZZA, L. (2000). RNA hyper-editing and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. *Hum. Mol. Genet.* **9**, 2297-2304.
- BENTLEY, D. (1999). Coupling RNA polymerase II transcription with pre-mRNA processing. *Curr. Opin. Cell Biol.* **11**, 347-351.
- BOISE, L.H., GONAZLEZ, G.M., POSTEMA, C.E., DING, L., LINDSTEN, T., TURKA, L.A., MAO, X., NUNEZ, G., and THOMPSON, C.B. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. *Cell* **74**, 597-608.
- BRAIS, B., BOUCHARD, J.P., XIE, Y.G., ROCHEFORT, D.L., CHRETIEN, N., TOME, F.M., LAFRENIERE, R.G., ROMMENS, J.M., UYAMA, E., NOHIRAO, *et al.* (1998). Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. *Nat. Genet.* **18**, 164-167.
- BRENNAN, C.M., and STEITZ, J.A. (2001). HuR and mRNA stability. *Cell. Mol. Life Sci.* **58**, 266-277.
- BURATTI, E., DORK, T., ZUCCATO, E., PAGANI, F., ROMANO, M., and BARALLE, F.E. (2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. *EMBO J.* **20**, 1774-1784.
- CACERES, J.F., and KORNBLIHTT, A.R. (2002). Alternative splicing: Multiple control mechanisms and involvement in human disease. *Trends Genet.* **18**, 186-193.
- CARTEGNI, L., CHEW, S.L., and KRAINER, A.R. (2002). Listening to silence and understanding nonsense: Exonic mutations that affect splicing. *Nat. Rev. Genet.* **3**, 285-298.
- CARTHEW, R.W. (2001). Gene silencing by double-stranded RNA. *Curr. Opin. Cell Biol.* **13**, 244-248.
- CATANIA, M.V., ARONICA, E., YANKAYA, B., and TROOST, D. (2001). Increased expression of neuronal nitric oxide synthase spliced variants in reactive astrocytes of amyotrophic lateral sclerosis human spinal cord. *J. Neurosci.* **21**, RC148.
- CELOTTO, A.M., and GRAVELEY, B.R. (2002). Exon-specific RNAi: A tool for dissecting the functional relevance of alternative splicing. *RNA* **8**, 718-724.
- CHANG, J.G., HSIEH-LI, H.M., JONG, Y.J., WANG, N.M., TSAI, C.H., and LI, H. (2001). Treatment of spinal muscular atrophy by sodium butyrate. *Proc. Natl. Acad. Sci. USA* **98**, 9808-9813.
- CHEN, W., KUBOTA, S., TERAMOTO, T., NISHIMURA, Y., YONEMOTO, K., and SEYAMA, Y. (1998). Silent nucleotide substitution in the sterol 27-hydroxylase gene (CYP 27) leads to alternative pre-mRNA splicing by activating a cryptic 5' splice site at the mutant codon in cerebrotendinous xanthomatosis patients. *Biochemistry* **37**, 4420-4428.
- CHESTER, A., SCOTT, J., ANANT, S., and NAVARATNAM, N. (2000). RNA editing: Cytidine to uridine conversion in apolipoprotein B mRNA. *Biochim. Biophys. Acta* **1494**, 1-13.
- COOPER, T.A., and MATTOX, W. (1997). The regulation of splice-site selection, and its role in human disease. *Am. J. Hum. Genet.* **61**, 259-266.
- COOVERT, D.D., LE, T.T., MCANDREW, P.E., STRASSWIMMER, J., CRAWFORD, T.O., MENDELL, J.R., COULSON, S.E., ANDROPHY, E.J., PRIOR, T.W., and BURGHESE, A.H. (1997). The survival motor neuron protein in spinal muscular atrophy. *Hum. Mol. Genet.* **6**, 1205-1214.

- COUCH, F.J., and WEBER, B.L. (1996). Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. *Hum. Mutat.* **8**, 8–18.
- CRAMER, P., CACERES, J.F., CAZALLA, D., KADENER, S., MURO, A.F., BARALLE, F.E., and KORNBLIHTT, A.R. (1999). Coupling of transcription with alternative splicing: RNA polIII promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. *Mol. Cell* **4**, 251–258.
- CRAMER, P., SREBROW, A., KADENER, S., WERBAJH, S., DE LA MATA, M., MELEN, G., NOGUES, G., and KORNBLIHTT, A.R. (2001). Coordination between transcription and pre-mRNA processing. *FEBS Lett.* **498**, 179–182.
- DAOUD, R., DA PENHA BERZAGHI, M., SIEDLER, F., HUBENER, M., and STAMM, S. (1999). Activity-dependent regulation of alternative splicing patterns in the rat brain. *Eur. J. Neurosci.* **11**, 788–802.
- DAOUD, R., MIES, G., KOPCZYSKA, A., OLÁH, L., HOSSMANN, K., and STAMM, S. (2002). Ischemia induces a translocation of the splicing factor tra2-beta1 and changes alternative splicing patterns in the brain. *J. Neurosci.* **22**, 5889–5899.
- DAOUD, R., STOILOV, P., STOSS, O., HÜBENER, M., BERZAGHI, M.D.P., HARTMANN, A.M., OLBRICH, M., and STAMM, S. (2000). Control of pre-mRNA processing by extracellular signals: From molecular mechanisms to clinical applications. *Gene Ther. Mol. Biol.* **5**, 141–150.
- DAS, S., LEVINSON, B., WHITNEY, S., VULPE, C., PACKMAN, S., and GITSCHIER, J. (1994). Diverse mutations in patients with Menkes disease often lead to exon skipping. *Am. J. Hum. Genet.* **55**, 883–889.
- DE MEIRLEIR, L., LISSENS, W., BENELLI, C., PONSOT, G., DESGUERRE, I., MARSAC, C., RODRIGUEZ, D., SAUDUBRAY, J.M., POGGI, F., and LIEBAERS, I. (1994). Aberrant splicing of exon 6 in the pyruvate dehydrogenase-E1 alpha mRNA linked to a silent mutation in a large family with Leigh's encephalomyelopathy. *Pediatr. Res.* **36**, 707–712.
- DIETZ, H.C., VALLE, D., FRANCOMANO, C.A., KENDZIOR, R.J., JR., PYERITZ, R.E., and CUTTING, G.R. (1993). The skipping of constitutive exons in vivo induced by nonsense mutations. *Science* **259**, 680–683.
- DOBKIN, C., and BANK, A. (1983). A nucleotide change in IVS 2 of a beta-thalassemia gene leads to a cryptic splice not at the site of the mutation. *Prog. Clin. Biol. Res.* **134**, 127–128.
- DOBKIN, C., PERGOLIZZI, R.G., BAHRE, P., and BANK, A. (1983). Abnormal splice in a mutant human beta-globin gene not at the site of a mutation. *Proc. Natl. Acad. Sci. USA* **80**, 1184–1188.
- DREDGE, B.K., POLYDORIDES, A.D., and DARNELL, R.B. (2001). The splice of life: Alternative splicing and neurological disease. *Nat. Rev. Neurosci.* **2**, 43–50.
- DREYFUSS, G., KIM, W.N., and KATAOKA, N. (2002). Messenger-RNA-binding proteins and the messages they carry. *Nat. Rev. Mol. Cell Biol.* **3**, 195–205.
- D'SOUZA, I., and SCHELLENBERG, G.D. (2000). Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusions. *J. Biol. Chem.* **275**, 17700–17709.
- D'SOUZA, I., POORKAI, P., HONG, M., NOCHLIN, D., LEE, V.M.-Y., BIRD, T.D., and SCHELLENBERG, G.D. (1999). Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. *Proc. Natl. Acad. Sci. USA* **96**, 5598–5603.
- ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**, 494–498.
- FRISCHMEYER, P.A., and DIETZ, H.C. (1999). Nonsense-mediated mRNA decay in health and disease. *Hum. Mol. Genet.* **8**, 1893–1900.
- FUJIMARU, M., TANAKA, A., CHOEH, K., WAKAMATSU, N., SAKURABA, H., and ISSHIKI, G. (1998). Two mutations remote from an exon/intron junction in the beta-hexosaminidase beta-subunit gene affect 3'-splice site selection and cause Sandhoff disease. *Hum. Genet.* **103**, 462–469.
- GAO, Q.S., MEMMOTT, J., LAFYATIS, R., STAMM, S., SCREATON, G., and ANDREADIS, A. (2000). Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. *J. Neurochem.* **74**, 490–500.
- GE, H., SI, Y., and WOLFFE, A.P. (1998). A novel transcriptional coactivator, p52, functionally interacts with the essential splicing factor ASF/SF2. *Mol. Cell* **2**, 751–759.
- GEHRING, N.H., FREDE, U., NEU-YILIK, G., HUNSDÖRFER, P., VETTER, B., HENTZE, M.W., and KULOZIK, A.E. (2001). Increased efficiency of mRNA 3' end formation: A new genetic mechanism contributing to hereditary thrombophilia. *Nat. Genet.* **28**, 389–392.
- GERBER, A.P., and KELLER, W. (2001). RNA editing by base deamination: More enzymes, more targets, new mysteries. *Trends Biochem. Sci.* **26**, 376–384.
- GILAD, S., KHOSRAVI, R., SHKEDY, D., UZIEL, T., ZIV, Y., SAVITSKY, K., ROTMAN, G., SMITH, S., CHESSA, L., JORGENSEN, T.J., *et al.* (1996). Predominance of null mutations in ataxia-telangiectasia. *Hum. Mol. Genet.* **5**, 433–439.
- GOEDERT, M., SPILLANTINI, M.G., CROWTHER, R.A., CHEN, S.G., PARCHI, P., TABATON, M., LANSKA, D.J., MARKESBERY, W.R., WILHELMSEN, K.C., DICKSON, D.W., *et al.* (1999). Tau gene mutation in familial progressive subcortical gliosis. *Nat. Med.* **5**, 454–457.
- GOETZ, J., CHATTON, B., MATTEI, M.G., and KEDINGER, C. (1996). Structure and expression of the ATFa gene. *J. Biol. Chem.* **271**, 29589–29598.
- GOODSON, M.L., PARK, S.O., and SARGE, K.D. (1995). Tissue-dependent expression of heat shock factor 2 isoforms with distinct transcriptional activities. *Mol. Cell Biol.* **15**, 5288–5293.
- GOTT, J.M., and EMESON, R.B. (2000). Functions and mechanisms of RNA editing. *Annu. Rev. Genet.* **34**, 499–531.
- GRABOWSKI, P. (1998). Splicing regulation in neurons: Tinkering with cell-specific control. *Cell* **92**, 709–712.
- GRABOWSKI, P.L., and BLACK, D.L. (2001). Alternative RNA splicing in the nervous system. *Prog. Neurobiol.* **65**, 289–308.
- GRAVELEY, B.R. (2000). Sorting out the complexity of SR protein functions. *RNA* **6**, 1197–1211.
- GRAVELEY, B.R. (2001). Alternative splicing: Increasing diversity in the proteomic world. *Trends Genet.* **17**, 99–108.
- HABELHAH, H., SHAH, K., HUANG, L., OSTARECK-LEDERER, A., BURLINGAME, A.L., SHOKAT, K.M., HENTZE, M.W., and RONAI, Z. (2001). ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. *Nat. Cell Biol.* **3**, 325–330.
- HANAMURA, A., CACERES, J.F., MAYEDA, A., FRANZA, B.R., and KRAINER, A.R. (1998). Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. *RNA* **4**, 430–444.
- HARRISON, P.M., KUMAR, A., LANG, N., SNYDER, M., and GERSTEIN, M. (2002). A question of size: The eukaryotic proteome and the problems in defining it. *Nucleic Acids Res.* **30**, 1083–1090.
- HARTMANN, A.M., RUJESCU, D., GIANNAKOUIROS, T., NIKOLAKAKI, E., GOEDERT, M., MANDELKOW, E.M., GAO, Q.S., ANDREADIS, A., and STAMM, S. (2001). Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. *Mol. Cell Neurosci.* **18**, 80–90.
- HASEGAWA, M., SMITH, M.J., IJIMA, M., TABIRA, T., and GOEDERT, M. (1999). FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. *FEBS Lett.* **443**, 93–96.
- HASEGAWA, Y., KAWAME, H., IDA, H., OHASHI, T., and ETO, Y. (1994). Single exon mutation in arylsulfatase A gene has two ef-

- fects: Loss of enzyme activity and aberrant splicing. *Hum. Genet.* **93**, 415–420.
- HASTINGS, M.L., and KRAINER, A.R. (2001). Pre-mRNA splicing in the new millennium. *Curr. Opin. Cell Biol.* **13**, 302–309.
- HENTZE, M.W., and KULOZIK, A.E. (1999). A perfect message: RNA surveillance and nonsense-mediated decay. *Cell* **96**, 307–310.
- HERBERT, A., and RICH, A. (1999). RNA processing and the evolution of eukaryotes. *Nat. Genet.* **21**, 265–269.
- HEROLD, A., SUYAMA, M., RODRIGUES, J.P., BRAUN, I.C., KUTAY, U., CARMO-FONSECA, M., BORK, P., and IZAURRALDE, E. (2000). TAP (NXF1) belongs to a multigene family of putative RNA export factors with a conserved modular architecture. *Mol. Cell Biol.* **20**, 8996–9008.
- HERTEL, K.J., and MANIATIS, T. (1998). The function of multisite splicing enhancers. *Mol. Cell* **1**, 449–455.
- HIGGS, D.R., WOOD, W.G., BARTON, C., and WEATHERALL, D.J. (1983). Clinical features and molecular analysis of acquired hemoglobin H disease. *Am. J. Med.* **75**, 181–191.
- HODGES, P.E., CARRICO, P.M., HOGAN, J.D., O'NEILL, K.E., OWEN, J.J., MANGAN, M., DAVIS, B.P., BROOKS, J.E., and GARRELS, J.I. (2002). Annotating the human proteome: The Human Proteome Survey Database (HumanPSD) and an in-depth target database for G protein-coupled receptors (GPCR-PD) from *Incyte Genomics*. *Nucleic Acids Res.* **30**, 137–141.
- HOFFMEYER, S., NURNBERG, P., RITTER, H., FAHSOLD, R., LEISTNER, W., KAUFMANN, D., and KRONE, W. (1998). Nearby stop codons in exons of the neurofibromatosis type 1 gene are disparate splice effectors. *Am. J. Hum. Genet.* **62**, 269–277.
- HOFMANN, Y., LORSON, C.L., STAMM, S., ANDROPHY, E.J., and WIRTH, B. (2000). Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). *Proc. Natl. Acad. Sci. USA* **97**, 9618–9623.
- HOGENESCH, J.B., CHING, K.A., BATALOV, S., SU, A.I., WALKER, J.R., ZHOU, Y., KAY, S.A., SCHULTZ, P.G., and COOKE, M.P. (2001). A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes. *Cell* **106**, 413–415.
- HOLLAND, P.M., SUZANNE, M., CAMPBELL, J.S., NOSELLI, S., and COOPER, J.A. (1997). MKK7 is a stress-activated mitogen-activated protein kinase kinase functionally related to hemipterous. *J. Biol. Chem.* **272**, 24994–24998.
- HUNTSMAN, M.M., TRAN, B.V., POTKIN, S.G., BUNNEY, W.E., JR., and JONES, E.G. (1998). Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. *Proc. Natl. Acad. Sci. USA* **95**, 15066–15071.
- HUTTON, M., LENDON, C.L., RIZZU, P., BAKER, M., FROELICH, S., HOULDEN, H., PICKERING-BROWN, S., CHAKRAVERTY, S., ISAACS, A., GROVER, A., *et al.* (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* **393**, 702–705.
- IJIMA, M., TABIRA, T., POORKAJ, P., SCHELLENBERG, G.D., TROJANOWSKI, J.Q., LEE, V.M., SCHMIDT, M.L., TAKAHASHI, K., NABIKA, T., MATSUMOTO, T., *et al.* (1999). A distinct familial presenile dementia with a novel missense mutation in the tau gene. *Neuroreport* **10**, 497–501.
- JABLONKA, S., SCHRANK, B., KRALEWSKI, M., ROSSOLL, W., and SENDTNER, M. (2000). Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: An animal model for spinal muscular atrophy type III. *Hum. Mol. Genet.* **9**, 341–346.
- JACOBSEN, M., SCHWEER, D., ZIEGLER, A., GABER, R., SCHOCK, S., SCHWINZER, R., WONIGEIT, K., LINDERT, R.B., KANTARCI, O., SCHAEFER-KLEIN, J., *et al.* (2000). A point mutation in PTPRC is associated with the development of multiple sclerosis. *Nat. Genet.* **26**, 495–499.
- JIN, Y., DIETZ, H.C., MONTGOMERY, R.A., BELL, W.R., MCINTOSH, I., COLLIER, B., and BRAY, P.F. (1996). Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. *J. Clin. Invest.* **98**, 1745–1754.
- KALBFUSS, B., MABON, S.A., and MISTELLI, T. (2001). Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. *J. Biol. Chem.* **276**, 42986–42993.
- KAMMA, H., POTMAN, D.S., and DREYFUSS, G. (1995). Cell type specific expression of hnRNP proteins. *Exp. Cell Res.* **221**, 187–196.
- KAUFER, D., FRIEDMAN, A., SEIDMAN, S., and SOREQ, H. (1998). Acute stress facilitates long-lasting changes in cholinergic gene expression. *Nature* **393**, 373–377.
- KEREM, B., and KEREM, E. (1996). The molecular basis for disease variability in cystic fibrosis. *Eur. J. Hum. Genet.* **4**, 65–73.
- KIM, V.N., and DREYFUSS, G. (2001). Nuclear mRNA binding proteins couple pre-mRNA splicing and post-splicing events. *Mol. Cells* **12**, 1–10.
- KIM, V.N., YONG, J., KATAOKA, N., ABEL, L., DIEM, M.D., and DREYFUSS, G. (2001). The Y14 protein communicates to the cytoplasm the position of exon-exon junctions. *EMBO J.* **20**, 2062–2068.
- KORADE-MIRNICS, Z., BABITZKE, P., and HOFFMAN, E. (1998). Myotonic dystrophy: Molecular windows on a complex etiology. *Nucleic Acids Res.* **26**, 1363–1368.
- KRAWCZAK, M., REISS, J., and COOPER, D.N. (1992). The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences. *Hum. Genet.* **90**, 41–54.
- KRECIC, A.M., and SWANSON, M.S. (1999). hnRNP complexes: Composition, structure, and function. *Curr. Opin. Cell Biol.* **11**, 363–371.
- LACERRA, G., SIERAKOWSKA, H., CARESTIA, C., FUCHAROEN, S., SUMMERTON, J., WELLER, D., and KOLE, R. (2000). Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. *Proc. Natl. Acad. Sci. USA* **97**, 9591–9596.
- LAN, N., HOWREY, R.P., LEE, S.W., SMITH, C.A., and SULLENGER, B.A. (1998). Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. *Science* **280**, 1593–1596.
- LANDER, E.S., LINTON, L.M., BIRREN, B., NUSBAUM, C., ZODY, M.C., BALDWIN, J., DEVON, K., DEWAR, K., DOYLE, M., FITZHUGH, W., *et al.* (2001). Initial sequencing and analysis of the human genome. *Nature* **409**, 860–921.
- LE CORRE, S., HARPER, C.G., LOPEZ, P., WARD, P., and CATTS, S. (2000). Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. *Neuroreport* **11**, 983–986.
- LEFEBVRE, S., BURGLEN, L., REBOULLET, S., CLERMONT, O., BURLET, P., VIOLLET, L., BENICHIU, B., CRUAUD, C., MILLASSEAU, P., ZEVIANI, M., *et al.* (1995). Identification and characterization of a spinal muscular atrophy-determining gene. *Cell* **80**, 155–165.
- LEFEBVRE, S., BURLET, P., LIU, Q., BERTRANDY, S., CLERMONT, O., MUNNICH, AR., DREYFUSS, G., and MELKI, J. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. *Nat. Genet.* **165**, 265–269.
- LEFUR, N., KELSALL, S.R., SILVERS, W.K., and MINTZ, B. (1997). Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: A projected basis for immunotherapy. *Proc. Natl. Acad. Sci. USA* **94**, 5332–5337.
- LEV-LEHMAN, E., EVRON, T., BROIDE, R.S., MESHORER, E., ARIEL, I., SEIDMAN, S., and SOREQ, H. (2000). Synaptogenesis and myopathy under acetylcholinesterase overexpression. *J. Mol. Neurosci.* **14**, 93–105.
- LEWIN, A.S., and HAUSWIRTH, W.W. (2001). Ribozyme gene ther-

- apy: Applications for molecular medicine. *Trends Mol. Med.* **7**, 221–228.
- LIM, S.R., and HERTEL, K.J. (2001). Modulation of SMN pre-mRNA splicing by inhibition of alternative 3' splice site pairing. *J. Biol. Chem.* **2**, 2.
- LIN, C., BRISTOL, L.A., JIN, L., DYKES-HOBERG, M., CRAWFORD, T., CLAWSON, L., and ROTHSTEIN, J.D. (1998). Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. *Neuron* **20**, 589–602.
- LIN, J., FRINTS, S., DUHAMEL, H., HEROLD, A., ABAD-RODRIGUES, J., DOTTI, C., IZAURRALDE E., MARYNEN, P., and FROYEN, G. (2001). NXF5, a novel member of the nuclear RNA export factor family, is lost in a male patient with a syndromic form of mental retardation. *Curr. Biol.* **11**, 1381–1391.
- LIU, H.X., CARTEGNI, L., ZHANG, M.Q., and KRAINER, A.R. (2001). A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. *Nat. Genet.* **27**, 55–58.
- LIU, W., QIAN, C., and FRANCKE, U. (1997). Silent mutation induces exon skipping of fibrillin-1 gene in Marfan syndrome. *Nat. Genet.* **16**, 328–329.
- LLEWELLYN, D.H., SCOBIE, G.A., URQUHART, A.J., WHATLEY, S.D., ROBERTS, A.G., HARRISON, P.R., and ELDER, G.H. (1996). Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: A synonymous codon mutation at –22 bp from the 5' splice site causes skipping of exon 3. *J. Med. Genet.* **33**, 437–438.
- LOMBARDI, P., HOFFER, M.J., TOP, B., DE WIT, E., GEVERS LEUVEN, J.A., FRANTS, R.R., and HAVEKES, L.M. (1993). An acceptor splice site mutation in intron 16 of the low density lipoprotein receptor gene leads to an elongated, internalization defective receptor. *Atherosclerosis* **104**, 117–128.
- LORSON, C.L., and ANDROPHY, E.J. (2000). An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. *Hum. Mol. Genet.* **9**, 259–265.
- LORSON, C.L., HAHNEN, E., ANDROPHY, E.J., and WIRTH, B. (1999). A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. *Proc. Natl. Acad. Sci. USA* **96**, 6307–6311.
- LU, X., TIMCHENKO, N.A., and TIMCHENKO, L.T. (1999). Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded in myotonic dystrophy. *Hum. Mol. Genet.* **8**, 53–60.
- LYNCH, K.W., and WEISS, A. (2001). A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. *J. Biol. Chem.* **276**, 24341–24347.
- MANIATIS, T., and REED, R. (2002). An extensive network of coupling among gene expression machines. *Nature* **416**, 499–506.
- MANLEY, J.L., and TACKE, R. (1996). SR proteins and splicing control. *Genes Dev.* **10**, 1569–1579.
- MANN, C.J., HONEYMAN, K., CHENG, A.J., LY, T., LLOYD, F., FLETCHER, S., MORGAN, J.E., PARTRIDGE, T.A., and WILTON, S.D. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. *Proc. Natl. Acad. Sci. USA* **98**, 42–47.
- MANSFIELD, S.G., KOLE, J., PUTTARAJU, M., YANG, C.C., GARCIA-BLANCO, M.A., COHN, J.A., and MITCHELL, L.G. (2000). Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. *Gene Ther.* **7**, 1885–1895.
- MAQUAT, L.E., and CARMICHAEL, G.G. (2001). Quality control of mRNA function. *Cell* **104**, 173–176.
- MCCORMICK, J.A., LYONS, V., JACOBSON, M.D., NOBLE, J., DIORIO, J., NYIRENDA, M., WEAVER, S., ESTER, W., YAU, J.L., MEANEY, M.J., *et al.* (2000). 5'-Heterogeneity of glucocorticoid receptor messenger RNA is tissue specific: Differential regulation of variant transcripts by early-life events. *Mol. Endocrinol.* **14**, 506–507.
- MCEWEN, B.S. (1999). Stress and hippocampal plasticity. *Annu. Rev. Neurosci.* **22**, 105–122.
- MCKIE, A.B., MCHALE, J.C., KEEN, T.J., TARTTELIN, E.E., GO-LIATH, R., VAN LITH-VERHOEVEN, J.J., GREENBERG, J., RAMESAR, R.S., HOYNG, C.B., CREMERS, F.P., *et al.* (2001). Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). *Hum. Mol. Genet.* **10**, 1555–1562.
- MEFFRE, E., DAVIS, E., SCHIFF, C., CUNNINGHAM-RUNDLES, C., IVASHKIV, L.B., STAUDT, L.M., YOUNG, J.W., and NUSSENZWEIG, M.C. (2000). Circulating human B cells that express surrogate light chains and edited receptors. *Nat. Immunol.* **1**, 207–213.
- MENDEL, J.T., and DIETZ, H.C. (2001). When the message goes awry: Disease-producing mutations that influence mRNA content and performance. *Cell* **107**, 411–414.
- MERCATANTE, D., and KOLE, R. (2000). Modification of alternative splicing pathways as a potential approach to chemotherapy. *Pharmacol. Ther.* **85**, 237–243.
- MESHORER, E., ERB, C., GAZIT, R., PAVLOVSKY, L., KAUFER, D., FRIEDMAN, A., GLICK, D., BEN-ARIE, N., and SOREQ, H. (2002). Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. *Science* **295**, 508–512.
- MESSIAEN, L., CALLENS, T., DE PAEPE, A., CRAEN, M., and MORTIER, G. (1997). Characterisation of two different nonsense mutations, C6792A and C6792G, causing skipping of exon 37 in the NF1 gene. *Hum. Genet.* **101**, 75–80.
- MINVIELLE-SEBASTIA, L., and KELLER, W. (1999). mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. *Curr. Opin. Cell Biol.* **11**, 352–357.
- MISTELI, T., CACERES, J.F., CLEMENT, J.Q., KRAINER, A.R., WILKINSON, M.F., and SPECTOR, D.L. (1998). Serine phosphorylation of SR proteins is required for their recruitment to sites of transcription in vivo. *J. Cell. Biol.* **143**, 297–307.
- MODREK, B., RESCH, A., GRASSO, C., and LEE, C. (2001). Genome-wide detection of alternative splicing in expressed sequences of human genes. *Nucleic Acids Res.* **29**, 2850–2859.
- MONANI, U.R., SENDTNER, M., COOVERT, D.D., PARSONS, D.W., ANDREASSI, C., LE, T.T., JABLONKA, S., SCHRANK, B., ROSSOL, W., PRIOR, T.W., *et al.* (2000). The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in *Smn*(^{-/-}) mice and results in a mouse with spinal muscular atrophy. *Hum. Mol. Genet.* **9**, 333–339.
- NABORS, L.B., GILLESPIE, G.Y., HARKINS, L., and KING, P.H. (2001). HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. *Cancer Res.* **61**, 2154–2161.
- NAKAI, K., and SAKAMOTO, H. (1994). Construction of a novel database containing aberrant splicing mutations of mammalian genes. *Gene* **141**, 171–177.
- NAYLER, O., STAMM, S., and ULLRICH, A. (1997). Characterization and comparison of four SR protein kinases. *Biochem. J.* **326**, 693–700.
- NAYLER, O., STRÄTLING, W., BOURQUIN, J.-P., STAGLJAR, I., LINDEMANN, L., JASPER, H., HARTMANN, A.M., FACKELMAYER, F.O., ULLRICH, A., and STAMM, S. (1998). SAF-B couples transcription and pre-mRNA splicing to SAR/MAR elements. *Nucleic Acids Res.* **26**, 3542–3549.
- NEUBAUER, G., KING, A., RAPPILBER, J., CALVIO, C., WATSON, M., AJUH, P., SLEEMAN, J., LAMOND, A., and MANN, M. (1998). Mass spectrometry and EST-database searching allows characterization of the multiprotein spliceosome complex. *Nat. Genet.* **20**, 46–50.
- NISSIM-RAFANIA, M., and KEREM, B. (2002). Splicing regulation as a potential genetic modifier. *Trends Genet.* **18**, 123–127.
- O'DONOVAN, C., APWEILER, R., and BAIROCH, A. (2001). The human proteomics initiative (HPI). *Trends Biotechnol.* **19**, 178–181.

- ORKIN, S.H., CHENG, T.C., ANTONARAKIS, S.E., and KAZAZIAN, H.H., JR. (1985). Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human beta-globin gene. *EMBO J.* **4**, 453–456.
- PADDISON, P.J., CAUDY, A.A., and HANNON, G.J. (2002). Stable suppression of gene expression by RNAi in mammalian cells. *Proc. Natl. Acad. Sci. USA* **99**, 1443–1448.
- PAGANI, F., BURATTI, E., STUANI, C., BENDIX, R., DORK, T., and BARALLE, F.E. (2002). A new type of mutation causes a splicing defect in ATM. *Nat. Genet.* **30**, 426–429.
- PALLADINO, M.J., KEEGAN, L.P., O'CONNELL, M.A., and REENAN, R.A. (2000). A-to-I pre-mRNA editing in *Drosophila* is primarily involved in adult nervous system function and integrity. *Cell* **102**, 437–449.
- PAUL, M.S., and BASS, B.L. (1998). Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. *EMBO J.* **17**, 1120–1127.
- PHILIPS, A.V., and COOPER, T.A. (2000). RNA processing and human disease. *Cell. Mol. Life Sci.* **57**, 235–249.
- PHILIPS, A.V., TIMCHENKO, L.T., and COOPER, T.A. (1998). Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. *Science* **280**, 737–741.
- PHUNG, T.L., SOWDEN, M.P., SPARKS, J.D., SPARKS, C.E., and SMITH, H.C. (1996). Regulation of hepatic apolipoprotein B RNA editing in the genetically obese Zucker rat. *Metabolism* **45**, 1056–1058.
- PLOOS VAN AMSTEL, J.K., BERGMAN, A.J., VAN BEURDEN, E.A., ROIJERS, J.F., PEELLEN, T., VAN DEN BERG, I.E., POLLTHE, B.T., KVVITTINGEN, E.A., and BERGER, R. (1996). Hereditary tyrosinemia type I: Novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; Variability of the genotype-phenotype relationship. *Hum. Genet.* **97**, 51–59.
- POORT, S.R., ROSENDAAL, F.R., REITSMA, P.H., and BERTINA, R.M. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* **88**, 3698–3703.
- PUTTARAJU, M., JAMISON, S.F., MANSFIELD, S.G., GARCIA-BLANCO, M.A., and MITCHELL, L.G. (1999). Spliceosome-mediated RNA *trans*-splicing as a tool for gene therapy. *Nat. Biotechnol.* **17**, 246–252.
- RABINOVICI, R., KABIR, K., CHEN, M., SU, Y., ZHANG, D., LUO, X., and YANG, J.H. (2001). ADAR1 is involved in the development of microvascular lung injury. *Circ. Res.* **88**, 1066–1071.
- RAITSKIN, O., CHO, D.S., SPERLING, J., NISHIKURA, K., and SPERLING, R. (2001). RNA editing activity is associated with splicing factors in hnRNP particles: The nuclear pre-mRNA processing machinery. *Proc. Natl. Acad. Sci. USA* **98**, 6571–6596.
- RAVE-HAREL, N., KEREM, E., NISSIM-RAFANIA, M., MADJAR, I., GOSHEN, R., AUGARTEN, A., RAHAT, A., HURWITZ, A., DARVASI, A., and KEREM, B. (1997). The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. *Am. J. Hum. Genet.* **60**, 87–94.
- REENAN, R.A. (2001). The RNA word meets behavior: A to I pre-mRNA editing in animals. *Trends Genet.* **17**, 53–56.
- REISS, J., DORCHE, C., STALLMEYER, B., MENDEL, R.R., COHEN, N., and ZABOT, M.T. (1999). Human molybdopterin synthase gene: Genomic structure and mutations in molybdenum cofactor deficiency type B. *Am. J. Hum. Genet.* **54**, 706–711.
- RUBIN, G.M. (2001). Comparing species. *Nature* **409**, 820–821.
- RUETER, S.M., DAWSON, T.R., and EMESON, R.B. (1999). Regulation of alternative splicing by RNA editing. *Nature* **399**, 75–80.
- SANTISTEBAN, I., ARREDONDO-VEGA, F.X., KELLY, S., LOUBSER, M., MEYDAN, N., ROIFMAN, C., HOWELL, P.L., BOWEN, T., WEINBERG, K.I., SCHROEDER, M.L. *et al.* (1995). Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: Implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA. *Hum. Mol. Genet.* **4**, 2081–2087.
- SATO, N., HORI, O., YAMAGUCHI, A., LAMBERT, J.C., CHARTIER-HARLIN, M.C., ROBINSON, P.A., DELACOURTE, A., SCHMIDT, A.M., FURUYAMA, T., IMAIZUMI, K., *et al.* (1999). A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. *J. Neurochem.* **72**, 2498–2505.
- SAVKUR, R.S., PHILIPS, A.V., and COOPER, T.A. (2001). Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. *Nat. Genet.* **29**, 40–47.
- SHAPIRA, M., TUR-KASPA, I., BOSGRAAF, L., LIVNI, N., GRANT, A.D., GRISARU, D., KORNER, M., EBSTEIN, R.P., and SOREQ, H. (2000). A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. *Hum. Mol. Genet.* **9**, 1273–1281.
- SHIROHIZU, H., YAMAZA, H., and FUKUMAKI, Y. (2000). Repression of aberrant splicing in human beta-globin pre-mRNA with HbE mutation by antisense oligoribonucleotide or splicing factor SF2/ASF. *Int. J. Hematol.* **72**, 28–33.
- SHOHAMI, E., KAUFER, D., CHEN, Y., SEIDMAN, S., COHEN, O., GINZBERG, D., MELAMED-BOOK, N., YIRMIYA, R., and SOREQ, H. (2000). Antisense prevention of neuronal damages following head injury in mice. *J. Mol. Med.* **78**, 228–236.
- SOREQ, H., and SEIDMAN, S. (2001). Acetylcholinesterase—New roles for an old actor. *Nat. Rev. Neurosci.* **2**, 294–302.
- SOSSI, V., GIULI, A., VITALI, T., TIZIANO, F., MIRABELLA, M., ANTONELLI, A., NERI, G., and BRAHE, C. (2001). Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype. *Eur. J. Hum. Genet.* **9**, 113–120.
- SPILLANTINI, M.G., and GOEDERT, M. (2001). Tau gene mutations and tau pathology in frontotemporal dementia and parkinsonism linked to chromosome 17. *Adv. Exp. Med. Biol.* **487**, 21–37.
- SPILLANTINI, M.G., MURRELL, J.R., GOEDERT, M., FARLOW, M.R., KLUG, A., and GHETTI, B. (1998). Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. *Proc. Natl. Acad. Sci. USA* **95**, 7737–7741.
- STAMM, S. (2002). Signals and their transduction pathways regulating alternative splicing: A new dimension of the human genome. *Hum. Mol. Genet.* **11**, 2409–2416.
- STAMM, S., ZHU, J., NAKAI, K., STOILOV, P., STOSS, O., and ZHANG, M.Q. (2000). An alternative-exon database and its statistical analysis. *DNA Cell Biol.* **19**, 739–756.
- STANFORD, P.M., HALLIDAY, G.M., BROOKS, W.S., KWOK, J.B., STOREY, C.E., CREASEY, H., MORRIS, J.G., FULHAM, M.J., and SCHOFIELD, P.R. (2000). Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations. *Brain* **123**, 880–893.
- STEINMETZ, E.J. (1997). Pre-mRNA processing and the CTD of RNA polymerase II: The tail that wags the dog? *Cell* **89**, 491–494.
- STICKELER, E., KITTRELL, F., MEDINA, D., and BERGET, S.M. (1999). Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. *Oncogene* **18**, 3574–3582.
- STOSS, O., OLBRICH, M., HARTMANN, A.M., KONIG, H., MEMMOTT, J., ANDREADIS, A., and STAMM, S. (2001). The STAR/GSG family protein rSLM-2 regulates the section of alternative splice sites. *J. Biol. Chem.* **276**, 8665–8673.
- STOSS, O., STOILOV, P., DAOUD, R., HARTMANN, A.M., OLBRICH, M., and STAMM, S. (2000). Misregulation of pre-mRNA splicing that causes human diseases. *Gene Ther. Mol. Biol.* **5**, 9–28.
- TACKE, R., and MANLEY, J.L. (1999). Determinants of SR protein specificity. *Curr. Opin. Cell Biol.* **11**, 358–362.

- TAKUMA, H., KWAK, S., YOSHIZAWA, T., and KANAZAWA, I. (1999). Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. *Ann. Neurol.* **46**, 806–815.
- TANABE, M., SASAI, N., NAGATA, K., LIU, X.D., LIU, P.C., THIELE, D.J., and NAKAI, A. (1999). The mammalian HSF4 gene generates both an activator and a repressor of heat shock genes by alternative splicing. *J. Biol. Chem.* **274**, 27845–27856.
- TARN, W.-Y., and STEITZ, J.A. (1997). Pre-mRNA splicing: The discovery of a new spliceosome doubles the challenge. *Trends Biol. Sci.* **22**, 132–137.
- TAVTIGIAN, S.V., SIMARD, J., TENG, D.H., ABTIN, V., BAUMGARD, M., BECK, A., CAMP, N.J., CARILLO, A.R., CHEN, Y., DAYANANTH, P., *et al.* (2001). A candidate prostate cancer susceptibility gene at chromosome 17p. *Nat. Genet.* **27**, 172–180.
- THANARAJ, T.A., and CLARK, F. (2001). Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. *Nucleic Acids Res.* **29**, 2581–2593.
- TIMMONS, L., and FIRE, A. (1998). Specific interference by ingested dsRNA. *Nature* **395**, 854.
- TISCORNIA, G., and MAHADEVAN, M.S. (2000). Myotonic dystrophy: The role of the CUG triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic DMPK mRNA isoform ratios. *Mol. Cell* **5**, 959–967.
- TOMKINS, O., KAUFER, D., KORN, A., SHELEF, I., GOLAN, H., REICHENTHAL, E., SOREQ, H., and FRIEDMAN, A. (2001). Frequent blood-brain barrier disruption in the human cerebral cortex. *Cell. Mol. Neurobiol.* **21**, 675–691.
- VAN DER HOUVEN VAN OORDT, W., DIAZ-MECO, M.T., LOZANO, J., KRAINER, A.R., MOSCAT, J., and CACERES, J.F. (2000). The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. *J. Cell Biol.* **149**, 307–316.
- VARANI, L., SPILLANTINI, M.G., GOEDERT, M., and VARANI, G. (2000). Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. *Nucleic Acids Res.* **28**, 710–719.
- VAWTER, M.P., FRYE, M.A., HEMPERLY, J.J., VANDERPUTTEN, D.M., USEN, N., DOHERTY, P., SAFFELL, J.L., ISSA, F., POST, R.M., WYATT, R.J., *et al.* (2000). Elevated concentration of N-CAM VASE isoforms in schizophrenia. *J. Psychiatr. Res.* **34**, 25–34.
- VEUGER, M.J., HONDERS, M.W., LANDEGENT, J.E., WILLEMZE, R., and BARGE, R.M. (2000). High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. *Blood* **96**, 1517–1524.
- VITALI, T., SOSSI, V., TIZIANO, F., ZAPPATA, S., GIULI, A., PARAVATOU-PETSOTAS, M., NERI, G., and BRAHE, C. (1999). Detection of the survival motor neuron (SMN) genes by FISH: Further evidence for a role for SMN2 in the modulation of disease severity in SMA patients. *Hum. Mol. Genet.* **8**, 2525–2532.
- VITHANA, E.N., ABU-SAFIEH, L., ALLEN, M.J., CAREY, A., PAPAIOANNOU, M., CHAKAROVA, C., AL-MAGHTHEH, M., EBENEZER, N.D., WILLIS, C., MOORE, A.T., *et al.* (2001). A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). *Mol. Cell* **8**, 375–381.
- WATANABE, T., and SULLENGER, B.A. (2000). Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. *Proc. Natl. Acad. Sci. USA* **97**, 8490–8494.
- WEG-REMERS, S., PONTA, H., HERRLICH, P., and KONIG, H. (2001). Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. *EMBO J.* **20**, 4194–4203.
- WEIGHARDT, F., BIAMONTI, G., and RIVA, S. (1996). The role of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. *BioEssays* **18**, 747–756.
- XAVIER, K.A., EDER, P.S., and GIORDANO, T. (2000). RNA as a drug target: Methods for biophysical characterization and screening. *Trends Biotechnol.* **18**, 349–356.
- XIE, J., and MCCOBB, D.P. (1998). Control of alternative splicing of potassium channels by stress hormones. *Science* **280**, 443–446.
- YAMANAKA, S., BALESTRA, M.E., FERRELL, L.D., FAN, J., ARNOLD, K.S., TAYLOR, S., TAYLOR, J.M., and INNERARITY, T.L. (1995). Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. *Proc. Natl. Acad. Sci. USA* **92**, 8483–8487.
- YU, L., HEERE-RESS, E., BOUCHER, B., DEFESCHE, J.C., KASTELEIN, J., LAVOIE, M.A., and GENEST, J., JR. (1999). Familial hypercholesterolemia. Acceptor splice site (G → C) mutation in intron 7 of the LDL-R gene: Alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(–1)G → C]. *Atherosclerosis* **146**, 125–131.
- ZAMORE, P.D. (2001). RNA interference: Listening to the sound of silence. *Nat. Struct. Biol.* **8**, 746–750.
- ZHANG, Q.X., HILSENBECK, S.G., FUQUA, S.A., and BORG, A. (1996). Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. *J. Steroid Biochem. Mol. Biol.* **59**, 251–260.
- ZHANG, Y., ZHOU, L., and MILLER, C.A. (1998). A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system. *Proc. Natl. Acad. Sci. USA* **95**, 2586–2591.
- ZILCH, C.F., WALKER, A.M., TIMON, M., GOFF, L.K., WALLACE, D.L., and BEVERLEY, P.C. (1998). A point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans. *Eur. J. Immunol.* **28**, 22–29.

Address reprint requests to:

Stefan Stamm, Ph.D.

University of Erlangen-Nuremberg

Institute of Biochemistry

Fahrstrasse 17

91054 Erlangen, Germany

E-mail: stefan@stamms-lab.net

Received for publication April 9, 2002; received in revised form July 20, 2002; accepted July 31, 2002.

This article has been cited by:

1. Noa Farchi, Shai Shoham, Binyamin Hochner, Hermona Soreq. 2007. Impaired hippocampal plasticity and errors in cognitive performance in mice with maladaptive AChE splice site selection. *European Journal of Neuroscience* **25**:1. . [[CrossRef](#)]
2. Daniela C. Glatz, Dan Rujescu, Yesheng Tang, Frank J. Berendt, Annette M. Hartmann, Frank Faltraco, Carlyn Rosenberg, Christine Hulette, Kurt Jellinger, Harald Hampel. 2006. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. *Journal of Neurochemistry* **96**:3, 635. [[CrossRef](#)]
3. E Meshorer, B Bryk, D Toiber, J Cohen, E Podoly, A Dori, H Soreq. 2005. SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. *Molecular Psychiatry* **10**:11, 985. [[CrossRef](#)]
4. Irena I. Artamonova, Mikhail S. Gelfand. 2004. Evolution of the Exon–Intron Structure and Alternative Splicing of the MAGE-A Family of Cancer/Testis Antigens. *Journal of Molecular Evolution* **59**:5, 620. [[CrossRef](#)]
5. Gil Ast. 2004. How did alternative splicing evolve?. *Nature Reviews Genetics* **5**:10, 773. [[CrossRef](#)]
6. Timothy R. Rebbeck, Margaret Spitz, Xifeng Wu. 2004. Assessing the function of genetic variants in candidate gene association studies. *Nature Reviews Genetics* **5**:8, 589. [[CrossRef](#)]
7. Fiona L. Wilkinson, James M. Holaska, Zhayi Zhang, Aarti Sharma, Sushila Manilal, Ian Holt, Stefan Stamm, Katherine L. Wilson, Glenn E. Morris. 2003. Emerin interacts in vitro with the splicing-associated factor, YT521-B. *European Journal of Biochemistry* **270**:11, 2459. [[CrossRef](#)]